MedTrace Logo

Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer

NCT00681967 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-09-23

No results posted yet for this study

Summary

To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa

Conditions

Interventions

DRUG

Gefitinib

250 mg; oral

DRUG

Gefitinib

250mg; oral

Sponsors & Collaborators

Principal Investigators

  • Christoph Rochlitz, Prof Dr med · University Hospital of Basel

  • Madeleine Billeter, MD · AstraZeneca AG, Grafenau 10; 6300 Zug; Switzerland

  • Verena Renggli · AstraZeneca AG, Grafenau 10; 6300 Zug; Switzerland

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00681967 on ClinicalTrials.gov